-+ 0.00%
-+ 0.00%
-+ 0.00%

VentriPoint re-grants and issues 6,392,750 stock options at $0.095 after shareholder approval of option plan

PUBT·08/07/2026 21:12:26
Listen to the news
VentriPoint re-grants and issues 6,392,750 stock options at $0.095 after shareholder approval of option plan
  • VentriPoint Diagnostics cancelled 4,301,250 stock options granted from Feb. 27, 2025 to May 27, 2026 due to missing annual shareholder approval.
  • Re-granted 3,151,250 of those options, including 1,000,000 to an officer; 250,000 previously cancelled options will not be re-granted.
  • Granted 3,241,500 annual incentive options at the July 8, 2026 market price; 6,392,750 options priced at $0.095.
  • Option terms run 2 to 10 years; vesting ranges from immediate to three years.
  • Treated 2,695,000 option grants and exercises as a non-brokered private placement at $0.1 to $0.12, effective July 29, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VentriPoint Diagnostics Ltd. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202608071710TNWSWRCACNPR_____1LPRFMe62) on August 07, 2026, and is solely responsible for the information contained therein.